Granted Patent
B2
US 12,679,860 · App. 18/667,496 · Granted Jul 14, 2026
C-terminal HSP90 inhibitors
Inventors:
Brian S.J. Blagg (Lawrence, KS); Bhaskar Reddy Kusuma (Lake Ronkonkoma, NY); Teather Sundstrom (Eckelson, ND)
Assignee:
UNIVERSITY OF KANSAS
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
Claims (21)
1 . A pharmaceutical composition comprising: a compound of the formula:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
2 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical acceptable carrier is a solid filler or excipient.
3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a solid.
4 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
5 . The pharmaceutical composition of claim 1 , wherein the compound is present in the pharmaceutical composition in a therapeutically effective amount.
6 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a compound of the formula:
7 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a tablet.
8 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a capsule.
9 . A method of treating or preventing a neurodegenerative disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .
10 . The method of claim 9 , wherein the neurodegenerative disorder is sensory neuron glucotoxicity.
11 . The method of claim 10 , wherein the sensory neuron glucotoxicity results from hyperglycemia.
12 . The method of claim 11 , wherein the hyperglycemia is associated with a diabetic condition.
13 . The method of claim 10 , wherein the sensory neuron glucotoxicity results in diabetic peripheral neuropathy.
14 . The method of claim 9 , wherein the method comprises treating the neurodegenerative disorder.
15 . The method of claim 14 , wherein the method comprises delaying or slowing the progression of the neurodegenerative disorder.
16 . The method of claim 14 , wherein the method ameliorates one or more symptoms of the neurodegenerative disorder.
17 . The method of claim 9 , wherein the method comprises preventing the neurodegenerative disorder.
18 . The method of claim 17 , wherein the method comprises delaying the onset of the neurodegenerative disorder.
19 . The method of claim 9 , wherein the therapeutically effective amount is an amount sufficient to inhibit the progression of the disorder.
20 . The method of claim 16 , wherein the symptom of the neurodegenerative disorder is pain.
Continuity (8)
Provisional Application
61597004
· Feb 9, 2012
References Cited (142)
US 7608594B2
· Blagg et al.
· 2009
[cited by applicant]
US 7622451B2
· Blagg et al.
· 2009
[cited by applicant]
US 7811998B2
· Blagg et al.
· 2010
[cited by applicant]
US 7960353B2
· Blagg
· 2011
[cited by applicant]
US 8212011B2
· Blagg
· 2012
[cited by applicant]
US 8212012B2
· Blagg
· 2012
[cited by applicant]
US 9056104B2
· Blagg et al.
· 2015
[cited by applicant]
US 9120774B2
· Blagg et al.
· 2015
[cited by applicant]
US 9422320B2
· Blagg et al.
· 2016
[cited by applicant]
US 9994556B2
· Zhao et al.
· 2018
[cited by applicant]
US 20110082098A1
· Calvet et al.
· 2011
[cited by applicant]
US 20130116227A1
· Katayama et al.
· 2013
[cited by applicant]
CN 101679347
· 2010
[cited by applicant]
CN 103596955
· 2014
[cited by applicant]
WO WO2006050501
· 2006
[cited by applicant]
WO WO2007095586
· 2007
[cited by applicant]
WO WO2008115719
· 2008
[cited by applicant]
WO WO2010096650
· 2010
[cited by applicant]
WO WO2011041593
· 2011
[cited by applicant]
WO WO2012138896
· 2012
[cited by applicant]
WO WO2012162054
· 2012
[cited by applicant]
WO WO2013119985
· 2013
[cited by applicant]
WO WO2015070091
· 2015
[cited by applicant]
WO WO2015070238
· 2015
[cited by applicant]
WO WO2015192099
· 2015
[cited by applicant]
WO WO2015200514
· 2015
[cited by applicant]
WO WO2019222269
· 2019
[cited by applicant]
Albermann et al. “Substrate specificity of NovM: implications for novobiocin biosynthesis and glycorandomization”,
[cited by applicant]
Alzheimer's disease, PubMed Health, Nov. 17, 2010.
[cited by applicant]
Ansar et al., “A non-toxic HSp90 inhibitor protects neurons from Abeta-induced toxicity,”
[cited by applicant]
Anyika et al., “Development of Noviomimetics as C-Terminal Hsp90 Inhibitors”,
[cited by applicant]
Avila et al., “High-throughput screening for Hsp90 ATPase inhibitors,”
[cited by applicant]
Bosseray et al., “What's new in vaccines against herpes simplex infections?”
[cited by applicant]
Boulton, et al., “Management of Diabetic Peripheral Neuropathy,”
[cited by applicant]
Burlison and Blagg, “Synthesis and Evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery,”
[cited by applicant]
Burlison et al., “Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines”,
[cited by applicant]
Burlison et al., “Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90”,
[cited by applicant]
Calkins et al., “The Nrf2/ARE Pathway as a Potential Therapeutic Target in Neurodegenerative Disease,”
[cited by applicant]
Cohen et al., “Novel C-Terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents,”
[cited by applicant]
Comer et al., “Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells,”
[cited by applicant]
Damasio, “Alzheimer's Disease and related dementias”, In: Cecil Textbook of Medicine, 20
[cited by applicant]
Donnelly and Blagg, “Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket,”
[cited by applicant]
Donnelly et al., “Cytotoxic sugar analogues of an optimized novobiocin scaffold,”
[cited by applicant]
Donnelly et al., “The Design, Synthesis, and Evaluation of Coumarin Ring Derivatives of the Novobiocin Scaffold that Exhibit Antiproliferative Activity”,
[cited by applicant]
Douglas, Jr., “Introduction to Viral Diseases”, In: Cecil Textbook of Medicine, 20
[cited by applicant]
Eikelenboom et al., “Inflammatory mechanisms in Alzheimer's disease,”
[cited by applicant]
Farmer et al., “KU-32, a novel drug for diabetic neuropathy, is safe for human islets and improves in vitro insulin secretion and viability,”
[cited by applicant]
Ferroud et al., “Synthesis and Biological Evaluation of Coumarincarboxylic Acids as Inhibitors of Gyrase B. L-Rhamnose as an Effective Substitute for L-Noviose,”
[cited by applicant]
Forsberg et al., “Modified buphenyl Hsp90 C-terminal inhibitors for the treatment of cancer,”
[cited by applicant]
Goff, “Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways”,
[cited by applicant]
Gura et al., “Systems for identifying new drugs are often faulty”,
[cited by applicant]
Hadden et al., “Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold,”
[cited by applicant]
Huang and Blagg, “A library of noviosylated coumarin analogues,”
[cited by applicant]
Huang et al., “Molecular Design of Anticancer Drug Leads Based on Three-Dimensional Quantitative Structure-Activity Relationship,”
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2013/025387, issued Aug. 12, 2014.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2013/025387, mailed Apr. 2, 2013.
[cited by applicant]
International Search Report and Written Opinion issued in International Patent Application No. PCT/US2015/037478, mailed Jan. 14, 2016.
[cited by applicant]
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials”,
[cited by applicant]
Kusuma et al., “Synthesis and Evaluation of Novologues as C-Terminal Hsp90 Inhibitors with Cytoprotective Activity against Sensory Neuron Glucotoxicity,”
[cited by applicant]
Kusuma et al., “Targeting the Heat Shock Protein 90 Dimer with Dimeric Inhibitors”,
[cited by applicant]
Layzer, “Degenerative diseases of the nervous system”, In: Cecil Textbook of Medicine, 20
[cited by applicant]
Lu et al., “Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line,”
[cited by applicant]
Ma et al., “Heat Shock Protein 70 Is Necessary to Improve Mitochondrial Bioenergetics and Reverse Diabetic Sensory Neuropathy following KU-32 Therapy,”
[cited by applicant]
Ma et al., “Modulating Molecular Chaperones Improves Mitochondrial Bioenergetics and Decreases the Inflammatory Transcriptome in Diabetic Sensory Neurons,”
[cited by applicant]
Marcu et al., “Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins,”
[cited by applicant]
Matts et al., “Elucidation of the Hsp90 C-Terminal Inhibitor Binding Site”,
[cited by applicant]
Mayer et al., “Hsp70 chaperones: cellular functions and molecular mechanism”,
[cited by applicant]
Mays et al., “The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone,”
[cited by applicant]
Moroni et al., “Exploiting Conformational Dynamics in Drug Discovery: Design of C-Terminal Inhibitors of Hsp90 with Improved Activities,”
[cited by applicant]
Office Communication issued in Chinese Application No. 201580033560.X, dated Aug. 3, 2018.
[cited by applicant]
Office Communication issued in corresponding Chinese Application No. 201380019057.X, dated Jul. 24, 2015. [English Translation].
[cited by applicant]
Office Communication issued in corresponding Eurasian Application No. 201491496, dated Aug. 10, 2015. [English Translation].
[cited by applicant]
Office Communication issued in corresponding European Application No. 13706822.7, dated Jun. 22, 2015.
[cited by applicant]
Office Communication issued in corresponding Korean Pat. Appl. No. 10-2014-7025348, mailed on Jul. 17, 2019. English translation appended.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 14/377,616, dated Oct. 1, 2015.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 14/377,616, dated Feb. 2, 2016.
[cited by applicant]
Parkinson's: Overview—PubMed Health, Apr. 8, 2015.
[cited by applicant]
Pearce et al., “Failure modes in anticancer drug discovery and development”, In: Cancer Drug Design and Discovery, ed. Stephen Neidle, chapter 18, pp. 424-435, 2008.
[cited by applicant]
Peterson and Blagg, “Click chemistry to probe Hsp90: synthesis and evaluation of a series of triazole-containing novobiocin analogues,”
[cited by applicant]
Peterson and Blagg, “To fold or not to fold: modulation and consequences of Hsp90 inhibition”,
[cited by applicant]
Razonable and Paya, “Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections”,
[cited by applicant]
Roos, “Huntington's disease: a clinical review,”
[cited by applicant]
Sadikot et al., “Development of a High-Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 Inhibitors,”
[cited by applicant]
Shelton et al., “KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemia cells,”
[cited by applicant]
Shen et al., “Synthesis of photolabile novobiocin analogues,”
[cited by applicant]
Simone, “Oncology: Introduction”, In: Cecil Textbook of Medicine, 20
[cited by applicant]
Urban et al., “Inhibiting Heat Shock Protein 90 Reverses Sensory Hypoalgesia in Diabetic Mice”,
[cited by applicant]
Urban et al., “Modulating Molecular Chaperones Improves Sensory Fiber Recovery and Mitochondrial Function in Diabetic Peripheral Neuropathy,”
[cited by applicant]
Vincent et al., “Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury”,
[cited by applicant]
Vincent et al., “Sensory Neurons and Schwann Cells Respond to Oxidative Stress by Increasing Antioxidant Defense Mechanisms”,
[cited by applicant]
Yu et al., “Hyperglycemia and downregulation of caveolin-1 enhance neuregulin-induced demyelination”,
[cited by applicant]
Yu et al., “Synthesis of Mono- and Dihydroxylated Furanoses, Pyranoses, and an Oxepanose for the Preparation of Natural Product Analogue Libraries,”
[cited by applicant]
Yu, et al., “Hsp90 inhibitors identified from a library of novobiocin analgoues,”
[cited by applicant]
Zhang et al., “Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production”,
[cited by applicant]
Zhang et al., “Simplified aminocoumarin analogues as anticancer agents: Amino isosteric replacement in the noviose moiety resulted in substantial enhancement of antiproliferative activity,”
[cited by applicant]
Zhang, et al., “C-Terminal Heat Shock Protein 90 Inhibitor Decreases Hyperglycemia-induced Oxidative Stress and Improves Mitochondrial Bioenergetics in Sensory Neurons,”
[cited by applicant]
Zhao and Blagg, “Novobiocin analogues with second-generation noviose surrogates,”
[cited by applicant]
Zhao and Blagg, In:
[cited by applicant]
Zhao et al., “3D-QSAR-assisted design, synthesis and evaluation of novobiocin analogues”,
[cited by applicant]
Zhao et al., “Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors,”
[cited by applicant]
Zhao et al., “Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents,”
[cited by applicant]
Zhao et al., “Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines”,
[cited by applicant]
Zhao et al., “Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative activity,”
[cited by applicant]
Zhao, et al., “3-Arylcoumarin Derivatives Manifest Anti-Proliferative Activity through Hsp90 Inhibition,”
[cited by applicant]
Zhao, et al., “Identification of a New Scaffold for Hsp90 C-Terminal Inhibition,”
[cited by applicant]
Declaration under 37 CFR 1.132 submitted in U.S. Appl. No. 14/377,616 on Jan. 1, 2016.
[cited by applicant]